Research Article

Antibacterial Activity of Murrayaquinone A and 6-Methoxy-3,7-dimethyl-2,3-dihydro-1H-carbazole-1,4(9H)-dione

Biswanath Chakraborty,1 Suchandra Chakraborty,2 and Chandan Saha2

1Department of Biochemistry & Medical Biotechnology, School of Tropical Medicine, Kolkata 700073, India
2Department of Clinical & Experimental Pharmacology, School of Tropical Medicine, Kolkata 700073, India

Correspondence should be addressed to Chandan Saha; katichandan@yahoo.co.in

Received 18 January 2014; Accepted 7 May 2014; Published 20 May 2014

1. Introduction

In 21st century, the most important and challenging problem to the medicinal chemists is to fight against the drug-resistant bacteria. It has been established that the antibacterial resistance is associated with an increase in morbidity and mortality. Frequently, it is recommended to use new antibacterial agents with enhanced broad-spectrum potency. Therefore, recent efforts have been intended for exploring novel antibacterial agents.

After the first isolation of Murrayanine, 3-formyl-1-methoxy carbazole, a carbazole alkaloid having antibiotic properties from Murraya koenigii Spreng [1–3], chemists have a significant interest in the field of carbazole alkaloids due to their interesting structural features and potential pharmacological activities [4–7]. Carbazole derivatives having nitrogen containing rigid aromatic heterocyclic moiety with desirable electronic charge transfer properties along with an extended \( \pi \)-conjugated system [8] exhibit diverse biological activities such as antibacterial [3, 9, 10], antifungal [11, 12], antiviral [13], anticancer [14], and various other activities. Besides the general antibacterial activity, carbazoles were shown to have a significant antituberculosis activity [15, 16]. This aspect is of interest to the present work, since the highest anti-TB activities were found for carbazole-1,4-quinones.

The enormous growth of carbazole chemistry has got novel prospect after the isolation of carbazomycins. Carbazomycin alkaloids 1–8 were first isolated by Nakamura and his group from Streptoverticillium ehimense H 1051-MY10 [17–23] as shown in Figure 1. In addition, literature survey showed that carbazomycins A, B, C, and D have also been successfully synthesized [24–27].

Carbazomycin A (1) and Carbazomycin B (2) have been found to be useful antibacterial and antifungal agents and Carbazomycin B was found to be the most potent among the carbazomycins. Both inhibit the growth of phytopathogenic fungi and exhibit antibacterial and antifeed activities [17]. Carbazomycin B (2) and Carbazomycin C (3) were shown to inhibit 5-lipoxygenase [28]. Carbazomycin G (7) shows antifungal activity against Trichophyton species [23]. In addition, extensive photophysical and photochemical properties [29–32] of carbazole nucleus have encouraged the researchers to explore for the synthesis of novel derivatives that have potential biological activities.
Synthesis of new molecules which are novel yet resemble well-known biologically active compounds by virtue of their critical structural similarity is the key feature of drug designing program. In this connection it is worthwhile to mention that 4-deoxycarbazomycin B (9) (Figure 2), a deoxygenated product of Carbazomycin B (2), presented considerable inhibitory activity [33] against various Gram-positive and Gram-negative bacteria. With the advancement in the synthesis of carbazomycin alkaloids, Carbazomycins G and H, which contain a unique quinol moiety, became an attractive synthetic target for several groups due to their challenging congested substitution pattern and their well-known biological activities. It is worth mentioning that first total syntheses of carbazomycins G and H were achieved by Knölker et al. [34–37]. Naturally occurring carbazoloquinone alkaloid, Murrayaquinone A (10), containing a quinone moiety having structural similarity with Carbazomycins G and H, has been detected to have a cardiotonic activity on the guinea pig papillary muscle [38]. In addition, during the development of the synthesis of Carbazomycin G [39] in our laboratory by a
new synthetic route, a new method is sprung up to obtain carbazoquinones via cerium-(IV) ammonium nitrate (CAN) mediated oxidation [40] of keto-tetrahydrocarbazoles. Consequently, we were able to prepare 6-methoxy-3,7-dimethyl-2,3-dihydro-1H-carbazole-1,4(9H)-dione (II) as well as Murrayaquinoine A (10) [41, 42]; both the compounds 10 and 11 (Figure 2) contain unique quinone moiety having structural resemblance to Carbazocin G (7). This structure-activity relationship boosted us to evaluate the antibacterial activity of these two synthesized compounds against Escherichia coli, Pseudomonas sp., Bacillus subtilis, and Staphylococcus aureus which are commonly used for the antimicrobial studies of carbazole derivatives.

2. Materials and Methods

2.1. Materials. Nutrient broth, Muller-Hinton broth, and agar powder were purchased from Himedia. Dimethylsulphoxide (DMSO) was purchased from E. Merck. Reference antibiotic disks were purchased from Himedia. The other materials were purchased from E. Merck (India). Compound 10 and compound 11 used in this work were synthesized in our laboratory.

2.2. Bacterial Cultures. Bacterial cultures of Escherichia coli (MTCC 42), Pseudomonas sp. (MTCC 6199), Bacillus subtilis (MTCC 111), and Staphylococcus aureus (MTCC 96) were obtained from the Microbial Type Culture Collection (MTCC), Institute of Microbial Technology (IMTECH), Chandigarh, India. These strains were maintained on nutrient agar slants, subcultured regularly (every 30 days), and stored at 4°C as well as at −80°C by preparing suspensions in 10% glycerol.

2.3. Synthesis of Murrayaquinoine A (10) and 6-Methoxy-3,7-dimethyl-2,3-dihydro-1H-carbazole-1,4(9H)-dione (II). A Claisen condensation [43] was carried out on 3-methylcyclohexanone with ethyl formate using metallic sodium in dry ether in presence of one drop of ethanol to furnish 4-methyl-2-oxocyclohexanecarbaldehyde (13). This formyl derivative (13) on subsequent condensation with proper phenylhydrazine [33] yielded 3-methylphenylhydrazono-cyclohexanone derivatives (15) which on acid catalysed Fischer Indole Cyclisation [33] in concentrated hydrochloric acid and glacial acetic acid mixture afforded ketotetrahydrocarbazole (16). Finally, CAN-SiO2 mediated oxidation [40] of 16 at room temperature furnished the expected quinones 10 and 11, respectively (Scheme 1).

**Scheme I: Synthesis of 10 and 11.**

**Compound 10.** m.p. 238°C (dec.). IR (KBr, ν cm⁻¹): 3443, 3217, 1662, 1635. UV λ max (MeOH): 222 (sh), 252, 380. 1H-NMR (DMSO-d6, 500 MHz) δ (ppm): 2.41 (s, 3H, C3-CH3), 6.55 (s, 1H, C2-H), 7.24 (s, 1H, C7-H), 7.41 (s, 1H, C8-H), 7.80 (s, 1H, C5-H). 13C-NMR (DMSO-d6, 125 MHz) δ (ppm): 15.57, 113.46, 114.93, 120.89, 123.89, 126.99, 128.01, 131.54, 135.75, 135.84, 147.85, 172.4, 1655, 1616. UV λ max (MeOH): 220, 258, 380. 1H-NMR (DMSO-d6, 500 MHz) δ (ppm): 2.03 (s, 3H, Ar-CH3), 2.43 (s, 3H, C3-CH3), 3.81 (s, 3H, Ar-OCH3), 6.67 (s, 1H, C2-H), 7.47 (s, 1H, C7-H), 7.58 (s, 1H, C8-H). 13C-NMR (DMSO-d6, 125 MHz) δ (ppm): 15.72, 16.31, 62.58, 113.22, 113.39, 117.54, 131.5, 131.65, 134.68, 137.55, 138.16, 146.08, 148.24, 179.48, 181.28. HRMS m/z: 278.0794 (Calcd for C13H13NO2Na: 278.0793).
Table 1: Protocol for the determination of minimum inhibitory concentration.

| Antibiotic stock (µg mL⁻¹) | Vol. of antibiotic (mL) | Vol. of water (mL) | Vol. of inoculum (mL) | Final vol. (mL) | Final concentration (µg mL⁻¹) |
|-----------------------------|-------------------------|-------------------|----------------------|----------------|-------------------------------|
| Nil                         | Nil                     | 2.5               | 0.00                 | 5              | Nil                           |
| Nil                         | Nil                     | 2.45              | 0.05                 | 5              | Nil                           |
| 500                         | 0.1                     | 2.35              | 0.05                 | 5              | 10                            |
| 500                         | 0.25                    | 2.20              | 0.05                 | 5              | 25                            |
| 500                         | 0.50                    | 1.95              | 0.05                 | 5              | 50                            |
| 500                         | 1.0                     | 1.45              | 0.05                 | 5              | 100                           |
| 4000                        | 0.2                     | 2.25              | 0.05                 | 5              | 160                           |
| 4000                        | 0.4                     | 2.05              | 0.05                 | 5              | 320                           |
| 4000                        | 0.6                     | 1.85              | 0.05                 | 5              | 480                           |
| 4000                        | 0.8                     | 1.65              | 0.05                 | 5              | 640                           |

2.4. Inoculum Preparation. Inoculums were prepared by transferring three to five well-isolated colonies of identical morphology to 5 mL sterile nutrient broth from the respective nutrient agar plates. The broth cultures were then incubated for 24 h at 37°C. Before the addition of inoculum the turbidity of the actively growing bacterial suspension was adjusted to match the turbidity standard of 0.5 McFarland units prepared by mixing 0.5 mL of 1.75% (w/v) barium chloride dihydrate with 99.5 mL 1% (v/v) sulphuric acid.

2.5. Antibacterial Activity Assay. Antibacterial activity was assayed with the standard agar well diffusion method (NCCLS 2000). Muller-Hinton agar plates were surface inoculated uniformly with 100 µL of overnight incubated bacterial suspension (10⁶ CFU/mL) and wells were cut from the agar. Test compounds were dissolved in DMSO and sterilized for 24 h at 37°C nutrient agar plates. The broth cultures were then incubated with 99.5 mL 1%(v/v)sulphuric acid. The final volume in each tube was adjusted by adding 2.5 mL of sterile nutrient broth.

2.6. Minimum Inhibitory Concentration (MIC) Determination. Minimum inhibitory concentration (MIC) of compound is defined as the lowest concentration that will inhibit the visible growth of a microorganism after overnight incubation. MIC values were determined by broth dilution method. The protocol used for this determination is shown in Table 1. The inoculum was prepared using overnight broth culture of each bacterial strain adjusted to a turbidity equivalent to a 0.5 McFarland standard. The final volume in each tube was adjusted by adding 2.5 mL of sterile nutrient broth.

3. Results and Discussions

In the present work the in vitro antibacterial activity of Murrayaquinone A (10) and 6-methoxy-3,7-dimethyl-2,3-dihydro-1H-carbazole-1,4(9H)-dione (11), obtained via the synthetic route (Scheme 1), was screened against Escherichia coli, Pseudomonas sp., Bacillus subtilis, and Staphylococcus aureus. The results are listed in Table 2. From the data it is clear that 3-methyl-1H-carbazole-1,4(9H)-dione (Murrayquinone A, 10) possess high activity against both of Escherichia coli and Staphylococcus aureus. It shows more activity against Staphylococcus aureus than Escherichia coli. On the other hand, 6-methoxy-3,7-dimethyl-2,3-dihydro-1H-carbazole-1,4(9H)-dione (11) has shown antibacterial activity only against Staphylococcus aureus.

As both these compounds have shown sensitivity against Staphylococcus aureus, we had performed the experiment for determining the minimum inhibitory concentration of compounds 10 and 11 against this organism. Results of this experiment are mentioned in Tables 3 and 4, respectively. Analysis of results shows that both these compounds have MIC value of 50 µg mL⁻¹ against Staphylococcus aureus.

As per our knowledge, this is the first report where antibacterial activity is detected on carbazoloquinone derivatives. Though the compounds exhibit antibacterial properties, they do not compare very well with generally used standard antibiotics. However, we are expecting that exploring this knowledge with some further structural modifications will yield promising results.

4. Conclusions

This report presents the pioneering findings on the potent antibacterial activity of compounds 10 and 11 against Staphylococcus aureus which has presently acquired resistance against many well-known antibiotics. Again novelty of these
Table 2: Result of antimicrobial activity assay by agar well diffusion method.

| Compound tested | \( E. \text{ coli} \) | \( B. \text{ subtilis} \) | \( S. \text{ aureus} \) | \( P. \text{ sp.} \) |
|-----------------|----------------|----------------|----------------|----------------|
|                 | \( A \)     | \( B \)     | \( C \) | \( A \)     | \( B \)     | \( C \) | \( A \)     | \( B \)     | \( C \) |
| ![Compound (10)](image1.png) | 20          | 18          | 18          | –ve         | –ve         | –ve         | 22          | 22          | 21          | –ve         | –ve         | –ve         |
| ![Compound (11)](image2.png) | –ve         | –ve         | –ve         | –ve         | –ve         | –ve         | 25          | 25          | 23          | –ve         | –ve         | –ve         |

Concentrations: \( A = 2560 \mu g \text{mL}^{-1} \); \( B = 1280 \mu g \text{mL}^{-1} \); \( C = 640 \mu g \text{mL}^{-1} \). Zone of inhibition given in mm (diameter). –ve: no inhibitory activity.
Table 3: Result of MIC determination of compound 10.

| Compound | Tube number | Antibiotic stock (µg mL⁻¹) | Final concentration of the tube (µg mL⁻¹) | Growth observed |
|----------|-------------|-----------------------------|-----------------------------------------|-----------------|
| CH₃O      | 0           | Nil                         | Nil                                     | -ve             |
|           | 1           | Nil                         | Nil                                     | +ve             |
|           | 2           | 500                         | 10                                      | +ve             |
|           | 3           | 500                         | 25                                      | +ve             |
|           | 4           | 500                         | 50                                      | -ve             |
|           | 5           | 500                         | 100                                     | -ve             |
|           | 6           | 4000                        | 160                                     | -ve             |
|           | 7           | 4000                        | 320                                     | -ve             |
|           | 8           | 4000                        | 480                                     | -ve             |
|           | 9           | 4000                        | 640                                     | -ve             |

synthesized compounds with highly efficient synthetic protocols, along with their pronounced antibacterial activities, largely supports them as potential antibiotics. Further research in this area is likely to yield potent antibacterial compounds against fast-developing and notorious drug resistant bacterial strains.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors are thankful to Professor Nandita Basu (Ghorai), Director, Professor Santanu Tripathi, Head of the Department of Clinical and Experimental Pharmacology, and Dr. Indrani Bhattacharyya, Assistant Professor, Department of Microbiology, School of Tropical Medicine, Kolkata, for their interest in the work. The authors would like to acknowledge Dr. Sanjoy Ghosh, Department of Biochemistry, University of Calcutta, for helpful suggestions. They are also thankful to The West Bengal University of Health Sciences for allowing them to do this work.

References

[1] D. P. Chakraborty, B. K. Barman, and P. K. Bose, “Structure of girinimbine, a pyranocarbazole derivative isolated from Murraya koenigii Spreng,” *Scientific Culture*, vol. 30, pp. 445–448, 1964.

[2] D. P. Chakraborty, B. K. Barman, and P. K. Bose, “On the constitution of murrayanine, a carbazole derivative isolated from Murraya koenigii Spreng,” *Tetrahedron*, vol. 21, no. 2, pp. 681–685, 1965.

[3] K. C. Das, D. P. Chakraborty, and P. K. Bose, “Antifungal activity of some constituents of Murraya koenigii spreng,” *Experientia*, vol. 21, no. 6, p. 340, 1965.

[4] H.-J. Knölliker and K. R. Reddy, “Isolation and synthesis of biologically active carbazole alkaloids,” *Chemical Reviews*, vol. 102, no. 11, pp. 4303–4427, 2002.

[5] H.-J. Knölliker, “Transition metal complexes in organic synthesis. Part 70: synthesis of biologically active carbazole alkaloids using organometallic chemistry,” *Current Organic Synthesis*, vol. 1, no. 4, pp. 309–331, 2004.

[6] I. Bauer and H.-J. Knölliker, “Synthesis of pyrrole and carbazole alkaloids,” *Topics in Current Chemistry*, vol. 309, pp. 203–253, 2012.

[7] A. W. Schmidt, K. R. Reddy, and H. J. Kn, “Occurrence, biogenesis, and synthesis of biologically active carbazole alkaloids,” *Chemical Reviews*, vol. 112, no. 6, pp. 3193–3328, 2012.
K. Yamasaki, M. Kaneda, and K. Watanabe, “New antibiotics,” 

C. Asche, W. Frank, A. Albert, and U. Kucklaender, “Synthesis, antitumour activity and structure-activity relationships of SH-benzo[b]carbazoles,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 3, pp. 819–837, 2005.

R. B. Bedford and M. Betham, “N-H carbazole synthesis from 2-chloroanilines via consecutive amination and C-H activation,” Journal of Organic Chemistry, vol. 71, no. 25, pp. 9403–9410, 2006.

R. B. Bedford, M. Betham, J. P. H. Charmant, and A. L. Weeks, “Intramolecular direct arylation in the synthesis of fluorinated carbazoles,” Tetrahedron, vol. 64, no. 26, pp. 6038–6050, 2008.

A. Bombrun and G. Casi, “N-Alkylation of 1H-indoles and 9H-carbazoles with alcohols,” Tetrahedron Letters, vol. 43, no. 12, pp. 2187–2190, 2002.

A. Bombrun, P. Gerber, G. Casi, O. Terradillos, B. Antonsson, and S. Halazy, “3,6-Dibromocarbazole piperazine derivatives of 2-propanol as first inhibitors of cytochrome C release via bax and S. Halazy,” 3,6-Dibromocarbazole piperazinederivatives of 2-propanol as first inhibitors of cytochrome C release via bax and S. Halazy,” Tetrahedron Letters, vol. 43, no. 12, pp. 2187–2190, 2002.

A. Bombrun, P. Gerber, G. Casi, O. TERRADILLOS, B. ANTONSSON, and S. HALAZY, “3,6-Dibromocarbazole piperazine derivatives of 2-propanol as first inhibitors of cytochrome C release via bax and S. HALAZY,” Tetrahedron Letters, vol. 43, no. 12, pp. 2187–2190, 2002.

K. Sakano, K. Ishimaru, and S. Nakamura, “New antibiotics, carbazomycins A and B: I: fermentation, extraction, purification and physico-chemical and biological properties,” Journal of Antibiotics, vol. 33, no. 7, pp. 683–689, 1980.

K. Sakano and S. Nakamura, “New antibiotics, carbazomycins A and B: II: structural elucidation,” Journal of Antibiotics, vol. 33, no. 9, pp. 961–966, 1980.

M. Kaneda, K. Sakano, S. Nakamura, Y. Kushi, and Y. Iitaka, “The structure of carbazomycin B,” Heterocycles, vol. 15, pp. 993–998, 1981.

K. Yamasaki, M. Kaneda, and K. Watanabe, “New antibiotics, carbazomycins A and B: I: fermentation, extraction, purification and physico-chemical and biological properties,” Journal of Antibiotics, vol. 36, no. 5, pp. 552–558, 1983.

S. Kondo, M. Katayama, and S. Marumo, “Carbazomycinal and 6-methoxycarbazomycinal as aerial mycelium formation-inhibitory substances of Streptoverticillium species,” Journal of Antibiotics, vol. 40, no. 5, pp. 727–730, 1976.

T. Naid, T. Kitahara, M. Kaneda, and S. Nakamura, “Carbazomycins C, D, E and F, minor components of the carbazomycin complex,” Journal of Antibiotics, vol. 40, no. 2, pp. 157–164, 1987.

M. Kaneda, T. Naid, T. Kitahara, S. Nakamura, T. Hirata, and T. Suga, “Carbazomycins G and H, novel carbazomycin-congeners containing a quinol moiety,” Journal of Antibiotics, vol. 41, no. 5, pp. 602–608, 1988.
[38] K. Takeya, M. Itoigawa, and H. Furukawa, “Triphasic inotropic response of guinea-pig papillary muscle to murrayaquinone-A isolated from Rutaceae,” European Journal of Pharmacology, vol. 169, no. 1, pp. 137–145, 1989.

[39] S. Chakraborty and C. Saha, “Total synthesis of carbazomycin G,” European Journal of Organic Chemistry, vol. 2013, no. 25, pp. 5731–5736, 2013.

[40] S. Chakraborty, G. Chattopadhyay, and C. Saha, “A novel CAN-SiO$_2$-mediated one-pot oxidation of 1-keto-1,2,3,4-tetrahydrocarbazoles to carbazoloquinones: efficient syntheses of murrayaquinone A and koeniginequinone A,” Journal of Heterocyclic Chemistry, vol. 48, no. 2, pp. 331–338, 2011.

[41] H.-J. Knölker and M. Bauermeister, “Transition metal-diene complexes in organic synthesis. 16: iron-mediated total synthesis of 1-oxygenated carbazole alkaloids,” Tetrahedron, vol. 49, no. 48, pp. 11221–11236, 1993.

[42] H.-J. Knölker and K. R. Reddy, “Indoloquinones. Part 8.1: palladium(II)-catalyzed total synthesis of murrayaquinone A, koeniginequinone A, and koeniginequinone B,” Heterocycles, vol. 60, no. 5, pp. 1049–1052, 2003.

[43] C. Ainsworth, “Indazole,” Organic Syntheses, vol. 4, pp. 536–539, 1963.